100 Active Studies

Erectile Dysfunction Clinical Trials Near You

Find 100 actively recruiting erectile dysfunction research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

100
Active Trials
282+
Locations
131,354
Participants Needed

Recruiting Studies

RecruitingNCT00785525

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

The purpose of the study is to: * Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors * Assess t...

4 locations(Boca Raton, Rockville, Minneapolis)
60,000 participants
Center for International Blood and Marrow Transplant Research
View Study Details
RecruitingNCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

10 locations(Jacksonville, Augusta, Chicago)
20,000 participants
UMC Utrecht
View Study Details
RecruitingNCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

10 locations(Birmingham, Phoenix, Auburn)
4,200 participants
American Society of Clinical Oncology
View Study Details
RecruitingNCT03486873

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

10 locations(Tucson, Bakersfield, Fresno)
3,500 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT04649242

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents....

10 locations(Birmingham, Scottsdale, Tempe)
2,100 participants
Pfizer
View Study Details
RecruitingNCT05438329

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors....

10 locations(Cerritos, Los Angeles, Margate)
1,123 participants
DualityBio Inc.
View Study Details
RecruitingNCT05535946

ABTECT - Maintenance

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with m...

10 locations(Birmingham, Dothan, Guntersville)
1,050 participants
Abivax S.A.
View Study Details
RecruitingNCT06541704

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...

10 locations(Phoenix, Phoenix, Phoenix)
975 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNCT06957080

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...

10 locations(Gilbert, Phoenix, Scottsdale)
960 participants
EyeBiotech Ltd.
View Study Details
RecruitingNCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from pati...

10 locations(Birmingham, Mobile, Anchorage)
960 participants
PedAL BCU, LLC
View Study Details
RecruitingNCT04626635

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors ...

10 locations(Los Angeles, Los Angeles, San Francisco)
933 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

10 locations(Miami, Sarasota, Atlanta)
787 participants
Eli Lilly and Company
View Study Details
RecruitingNCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

10 locations(Duarte, New Haven, Kissimmee)
740 participants
Daiichi Sankyo
View Study Details
RecruitingNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

10 locations(La Jolla, Los Angeles, Sacramento)
727 participants
Immunocore Ltd
View Study Details
RecruitingNCT05768139

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

10 locations(Los Angeles, San Francisco, Aurora)
720 participants
Eli Lilly and Company
View Study Details
RecruitingNCT04638647

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment w...

10 locations(Fullerton, La Mesa, San Leandro)
715 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06480383

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in ...

10 locations(Chandler, Phoenix, Encino)
705 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingNCT05417594

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

10 locations(La Jolla, Los Angeles, San Francisco)
695 participants
AstraZeneca
View Study Details
RecruitingNCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

10 locations(Tucson, La Jolla, Los Angeles)
680 participants
Immunocore Ltd
View Study Details
RecruitingNCT05094336

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and ...

10 locations(Duarte, Glendale, Oxnard)
649 participants
Amgen
View Study Details
RecruitingNCT06994442

Optimizing Pain Treatment in Children On Mechanical Ventilation

In this clinical trial, investigators want to learn more about using non-opioid pain medications for children with acute respiratory failure. Right now, doctors give these children opioids to help wit...

10 locations(Little Rock, Washington D.C., Ann Arbor)
644 participants
Weill Medical College of Cornell University
View Study Details
RecruitingNCT05156398

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine....

10 locations(Fort Smith, Hawthorne, La Mesa)
640 participants
Pfizer
View Study Details
RecruitingNCT04108156

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...

10 locations(Mesa, Phoenix, Phoenix)
634 participants
Hoffmann-La Roche
View Study Details
RecruitingNCT02339571

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melan...

10 locations(Birmingham, Kingman, Little Rock)
600 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT05722938

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sC...

10 locations(Mobile, Fresno, Sacramento)
590 participants
Biotest
View Study Details
RecruitingNCT05489211

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Ad...

10 locations(Los Angeles, San Diego, Santa Rosa)
582 participants
AstraZeneca
View Study Details
RecruitingNCT06701903

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Stati...

10 locations(Little Rock, Culver City, Encino)
570 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingNCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that ha...

10 locations(Phoenix, Tucson, Los Angeles)
569 participants
Genmab
View Study Details
RecruitingNCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

9 locations(Sarasota, Grand Rapids, San Antonio)
550 participants
BioNTech SE
View Study Details
RecruitingNCT06850922

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1...

10 locations(Phoenix, Phoenix, Phoenix)
546 participants
Genentech, Inc.
View Study Details
RecruitingNCT03526835

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC...

10 locations(La Jolla, Los Angeles, San Diego)
523 participants
Merus N.V.
View Study Details
RecruitingNCT06380751

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...

10 locations(Gilbert, Glendale, Los Angeles)
500 participants
AstraZeneca
View Study Details
RecruitingNCT06311214

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

10 locations(Encinitas, La Jolla, San Diego)
500 participants
National Cancer Institute (NCI)
View Study Details
RecruitingNCT05267821

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

10 locations(Birmingham, Little Rock, Los Angeles)
500 participants
Nationwide Children's Hospital
View Study Details
RecruitingNCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

10 locations(Duarte, Glendale, La Jolla)
500 participants
Turning Point Therapeutics, Inc.
View Study Details
RecruitingNCT05875168

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

10 locations(Sarasota, Portland, Providence)
470 participants
Daiichi Sankyo
View Study Details
RecruitingNCT06334432

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid...

8 locations(Detroit, Hackensack, New York)
466 participants
Nuvation Bio Inc.
View Study Details
RecruitingNCT06201676

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

The goal of this randomized clinical trial is to learn if the use of a low-dose nonsteroidal anti-inflammatory drug (NSAID), ketorolac, reduces the rate of chronic opioid use in orthopaedic polytrauma...

2 locations(Boston, Nashville)
458 participants
Massachusetts General Hospital
View Study Details
RecruitingNCT05410145

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

10 locations(Orange, Denver, Sarasota)
442 participants
D3 Bio (Wuxi) Co., Ltd
View Study Details
RecruitingNCT06581432

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...

10 locations(Anchorage, Tucson, Beverly Hills)
430 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT04977453

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or lo...

8 locations(New York, Huntersville, Daejeon)
430 participants
GI Innovation, Inc.
View Study Details
RecruitingNCT07197827

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

10 locations(New Haven, Sarasota, Boston)
424 participants
MediLink Therapeutics (Suzhou) Co., Ltd.
View Study Details
RecruitingNCT03996265

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depr...

10 locations(Anchorage, Anchorage, Anchorage)
422 participants
University of Rochester NCORP Research Base
View Study Details
RecruitingNCT06953869

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with...

3 locations(Winter Park, Charlotte, San Antonio)
420 participants
Vanda Pharmaceuticals
View Study Details
RecruitingNCT06033599

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake...

2 locations(New Brunswick, Salt Lake City)
420 participants
Rutgers, The State University of New Jersey
View Study Details
RecruitingNCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

10 locations(Irvine, Los Angeles, Aurora)
413 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT06264180

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage III...

10 locations(Gilbert, La Jolla, Los Angeles)
400 participants
Replimune Inc.
View Study Details
RecruitingNCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

10 locations(Ann Arbor, Durham, Columbus)
400 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT07064759

Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...

3 locations(Sun City, Hagerstown, Nashville)
400 participants
4D Molecular Therapeutics
View Study Details
RecruitingNCT06998407

Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in pat...

8 locations(Los Angeles, New Haven, Boston)
380 participants
Avenzo Therapeutics, Inc.
View Study Details
RecruitingNCT04143711

Study of DF1001 in Patients with Advanced Solid Tumors

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase ...

10 locations(Irvine, Los Angeles, San Diego)
378 participants
Dragonfly Therapeutics
View Study Details
RecruitingNCT05123482

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

10 locations(Duarte, Irvine, Santa Monica)
370 participants
AstraZeneca
View Study Details
RecruitingNCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cance...

10 locations(Aurora, Boston, New York)
370 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with ad...

10 locations(Loma Linda, Sacramento, Denver)
365 participants
Marengo Therapeutics, Inc.
View Study Details
RecruitingNCT06730750

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5....

6 locations(Los Angeles, Grand Rapids, Hackensack)
360 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05301413

Social Determinants and a Diabetes Prevention Program Tailored for African Americans

African Americans (AAs) have rates of diabetes mellitus (DM) twice that of Whites and are disproportionately affected by leading risk factors for DM - obesity and low-income. A critical strategy in th...

2 locations(Kansas City, Kansas City)
360 participants
University of Missouri, Kansas City
View Study Details
RecruitingNCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

10 locations(Scottsdale, Jacksonville, Rochester)
358 participants
GI Innovation, Inc.
View Study Details
RecruitingNCT05684965

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

10 locations(Sacramento, New Haven, Saint Louis Park)
358 participants
Xilio Development, Inc.
View Study Details
RecruitingNCT05077904

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no re...

10 locations(Phoenix, Scottsdale, Little Rock)
350 participants
UCB Biopharma SRL
View Study Details
RecruitingNCT05315700

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

10 locations(Duarte, Huntington Beach, Irvine)
350 participants
ORIC Pharmaceuticals
View Study Details
RecruitingNCT05081609

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose exp...

10 locations(Los Angeles, Los Angeles, Springfield)
345 participants
Ascendis Pharma Oncology Division A/S
View Study Details
RecruitingNCT05320588

A Study in Patients With Advanced Cancers

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers....

3 locations(Austin, Houston, Fairfax)
332 participants
BiOneCure Therapeutics Inc.
View Study Details
RecruitingNCT04983810

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID. This study con...

4 locations(Duarte, Houston, Seoul)
330 participants
Cyclacel Pharmaceuticals, Inc.
View Study Details
RecruitingNCT05156983

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagu...

10 locations(Sacramento, Torrance, Englewood)
328 participants
Takeda
View Study Details
RecruitingNCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

6 locations(Scottsdale, Denver, New Haven)
316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingNCT06846320

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess ho...

10 locations(Huntsville, Phoenix, Tucson)
315 participants
AbbVie
View Study Details
RecruitingNCT05434234

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

10 locations(Fair Oaks, La Jolla, Lone Tree)
312 participants
MediLink Therapeutics (Suzhou) Co., Ltd.
View Study Details
RecruitingNCT06635148

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....

10 locations(Tucson, Fullerton, La Jolla)
311 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT06188702

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygo...

10 locations(Los Angeles, San Francisco, Lake Mary)
308 participants
Servier Bio-Innovation LLC
View Study Details
RecruitingNCT06962839

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic mac...

10 locations(Arcadia, Modesto, Pasadena)
300 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT05398484

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

2 locations(Aurora, New York)
300 participants
NYU Langone Health
View Study Details
RecruitingNCT06072482

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)....

10 locations(Anchorage, Scottsdale, Surprise)
300 participants
Amgen
View Study Details
RecruitingNCT05941507

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expa...

8 locations(Los Angeles, Boston, Ann Arbor)
300 participants
LigaChem Biosciences, Inc.
View Study Details
RecruitingNCT04005378

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...

3 locations(Lauderdale Lakes, Grand Rapids, Kalamazoo)
300 participants
Northwell Health
View Study Details
RecruitingNCT05584670

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

10 locations(Newark, Iowa City, Fairway)
291 participants
Sanofi
View Study Details
RecruitingNCT06384807

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

10 locations(Duarte, La Jolla, Palo Alto)
280 participants
Biohaven Therapeutics Ltd.
View Study Details
RecruitingNCT06143787

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

The purpose of this study is to assess the effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple t...

10 locations(Loma Linda, Stamford, Millcreek)
280 participants
Hyloris Developments
View Study Details
RecruitingNCT05443126

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)...

10 locations(Los Angeles, Stanford, Washington D.C.)
265 participants
Ellipses Pharma
View Study Details
RecruitingNCT06685068

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This tri...

3 locations(Grand Rapids, San Antonio, West Valley City)
260 participants
Genmab
View Study Details
RecruitingNCT05830097

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in ...

5 locations(Cerritos, Orlando, Manhasset)
260 participants
Coherent Biopharma (Hefei) Co., Ltd.
View Study Details
RecruitingNCT04867837

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor proth...

10 locations(Torrance, Gainesville, West Palm Beach)
260 participants
Octapharma
View Study Details
RecruitingNCT06953583

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, ...

10 locations(Los Angeles, Gainesville, Tampa)
255 participants
Biogen
View Study Details
RecruitingNCT03746431

A Phase 1 Study of [225Ac]-FPI-1434 Injection

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434...

10 locations(Duarte, Boston, Minneapolis)
253 participants
Fusion Pharmaceuticals Inc.
View Study Details
RecruitingNCT06572228

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breat...

10 locations(Bakersfield, La Jolla, Lancaster)
250 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNCT06809595

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama...

10 locations(Little Rock, Los Angeles, Los Angeles)
250 participants
Mind Medicine, Inc.
View Study Details
RecruitingNCT05699174

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, ...

10 locations(Indianapolis, Baltimore, Minneapolis)
250 participants
Major Extremity Trauma Research Consortium
View Study Details
RecruitingNCT04145622

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. Th...

10 locations(Los Angeles, Denver, Orlando)
250 participants
Daiichi Sankyo
View Study Details
RecruitingNCT06425159

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label...

10 locations(Birmingham, Phoenix, Phoenix)
242 participants
Biohaven Therapeutics Ltd.
View Study Details
RecruitingNCT05597839

Study of DF9001 in Patients With Advanced Solid Tumors

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase ...

10 locations(Gilbert, Phoenix, Irvine)
242 participants
Dragonfly Therapeutics
View Study Details
RecruitingNCT06470763

A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or ...

10 locations(Detroit, Philadelphia, Houston)
240 participants
Anaveon AG
View Study Details
RecruitingNCT06130553

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

10 locations(San Francisco, West Hollywood, New Haven)
234 participants
AstraZeneca
View Study Details
RecruitingNCT04301765

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer...

3 locations(Augusta, Boston, Seattle)
230 participants
Seattle Institute for Biomedical and Clinical Research
View Study Details
RecruitingNCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tum...

10 locations(Irvine, Irvine, Los Angeles)
230 participants
PMV Pharmaceuticals, Inc
View Study Details
RecruitingNCT05382338

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers t...

10 locations(Birmingham, Mobile, Phoenix)
225 participants
Children's Oncology Group
View Study Details
RecruitingNCT06305247

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have ...

10 locations(Los Angeles, San Diego, New Haven)
220 participants
Ipsen
View Study Details
RecruitingNCT04421820

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and...

10 locations(Santa Monica, Tampa, Edmonton)
220 participants
Bold Therapeutics, Inc.
View Study Details
RecruitingNCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors ha...

3 locations(Huntersville, Austin, Fairfax)
205 participants
Terremoto Biosciences Inc.
View Study Details
RecruitingNCT06635785

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....

10 locations(Birmingham, Springdale, Gainesville)
204 participants
OncoC4, Inc.
View Study Details
RecruitingNCT06660654

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadhe...

10 locations(East Brunswick, Albany, New York)
200 participants
Daiichi Sankyo
View Study Details
RecruitingNCT06795412

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

3 locations(Boston, Houston, Fairfax)
200 participants
Pyxis Oncology, Inc
View Study Details

Top Cities for Erectile Dysfunction Clinical Trials

Erectile Dysfunction clinical trials are recruiting across 282 cities. Here are the cities with the most active studies:

About Erectile Dysfunction

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

Clinical trials are advancing new treatments for erectile dysfunction. Currently, 100 studies are recruiting a combined 131,354 participants across the United States. Research is being conducted by 76 organizations including Center for International Blood and Marrow Transplant Research, UMC Utrecht, American Society of Clinical Oncology and 73 others.

2026 Erectile Dysfunction Research Landscape

As of March 2026, the erectile dysfunction clinical trial landscape includes 100 actively recruiting studies across 282 cities in the United States. These studies are collectively seeking 131,354 participants, with an average enrollment target of 1,314 per study.

Research is being led by 76 different organizations, including Center for International Blood and Marrow Transplant Research, UMC Utrecht, American Society of Clinical Oncology, Merck Sharp & Dohme LLC, Pfizer, and 71 others. The large number of sponsors reflects significant research interest and investment in erectile dysfunction treatment advancement.

Geographically, erectile dysfunction trials are most concentrated in Los Angeles, California (43 trials); Boston, Massachusetts (28 trials); New York, New York (24 trials); Phoenix, Arizona (22 trials); La Jolla, California (17 trials) and 7 other cities.

Featured Erectile Dysfunction Studies

Highlighted recruiting studies for erectile dysfunction, selected by enrollment size and research scope.

RecruitingNCT00785525

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

The purpose of the study is to: * Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors * Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis * Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant reci...

Sponsor: Center for International Blood and Marrow Transplant Research· 60,000 participants· 4 locations (Boca Raton, Rockville, Minneapolis, New York)
View full study details →
RecruitingNCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in ...

Sponsor: UMC Utrecht· 20,000 participants· 10 locations (Jacksonville, Augusta, Chicago, New Orleans)
View full study details →
RecruitingNCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a pat...

Sponsor: American Society of Clinical Oncology· 4,200 participants· 10 locations (Birmingham, Phoenix, Auburn, Berkeley)
View full study details →

Frequently Asked Questions About Erectile Dysfunction Clinical Trials

Are there erectile dysfunction clinical trials near me?

Yes, there are 100 erectile dysfunction clinical trials currently recruiting across 282+ cities in the United States, including Los Angeles, California; Boston, Massachusetts; New York, New York. Browse the studies above to find one at a location convenient for you.

How do I join a erectile dysfunction clinical trial?

To join a erectile dysfunction clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are erectile dysfunction clinical trials free?

Yes, participation in erectile dysfunction clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of erectile dysfunction treatments are being studied?

Current erectile dysfunction clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 76 research organizations.

Is it safe to participate in erectile dysfunction clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 2, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 2, 2026 · Data from ClinicalTrials.gov